Automated blood glucose control in type 1 diabetes: A review of progress and challenges.

Since the 2000s, research teams worldwide have been working to develop closed-loop (CL) systems able to automatically control blood glucose (BG) levels in patients with type 1 diabetes. This emerging technology is known as artificial pancreas (AP), and its first commercial version just arrived in the market. The main objective of this paper is to present an extensive review of the clinical trials conducted since 2011, which tested various implementations of the AP for different durations under varying conditions. A comprehensive table that contains key information from the selected publications is provided, and the main challenges in AP development and the mitigation strategies used are discussed. The development timelines for different AP systems are also included, highlighting the main evolutions over the clinical trials for each system.

[1]  Sue Simpson,et al.  Artificial Pancreas Device Systems for the Closed-Loop Control of Type 1 Diabetes , 2015, Journal of diabetes science and technology.

[2]  E. Atlas,et al.  The “Glucositter” overnight automated closed loop system for type 1 diabetes: A randomized crossover trial , 2013, Pediatric Diabetes.

[3]  Ali Cinar,et al.  An Integrated Multivariable Artificial Pancreas Control System , 2014, Journal of diabetes science and technology.

[4]  Ahmad Haidar,et al.  The role of glucagon in the artificial pancreas. , 2016, The lancet. Diabetes & endocrinology.

[5]  Ali Cinar,et al.  Meal Detection in Patients With Type 1 Diabetes: A New Module for the Multivariable Adaptive Artificial Pancreas Control System , 2016, IEEE Journal of Biomedical and Health Informatics.

[6]  Giovanni Sparacino,et al.  Improving Accuracy and Precision of Glucose Sensor Profiles: Retrospective Fitting by Constrained Deconvolution , 2014, IEEE Transactions on Biomedical Engineering.

[7]  David Kerr,et al.  The effect of evening alcohol consumption on next-morning glucose control in type 1 diabetes. , 2001, Diabetes care.

[8]  Roman Hovorka,et al.  Safety of closed‐loop therapy during reduction or omission of meal boluses in adolescents with type 1 diabetes: a randomized clinical trial , 2014, Diabetes, obesity & metabolism.

[9]  Roman Hovorka,et al.  The future of continuous glucose monitoring: closed loop. , 2008, Current diabetes reviews.

[10]  David M Nathan,et al.  Outpatient glycemic control with a bionic pancreas in type 1 diabetes. , 2014, The New England journal of medicine.

[11]  G. Steil,et al.  Impact of Fat, Protein, and Glycemic Index on Postprandial Glucose Control in Type 1 Diabetes: Implications for Intensive Diabetes Management in the Continuous Glucose Monitoring Era , 2015, Diabetes Care.

[12]  D G Altman,et al.  Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists , 2011, BMJ : British Medical Journal.

[13]  J. Hans DeVries,et al.  Feasibility of a Bihormonal Closed-Loop System to Control Postexercise and Postprandial Glucose Excursions , 2012, Journal of diabetes science and technology.

[14]  Claudio Cobelli,et al.  Closed-Loop Artificial Pancreas Systems: Physiological Input to Enhance Next-Generation Devices , 2014, Diabetes Care.

[15]  K. Turksoy,et al.  Multivariable adaptive closed-loop control of an artificial pancreas without meal and activity announcement. , 2013, Diabetes technology & therapeutics.

[16]  Neesha Ramchandani,et al.  Role of Glucagon-Like Peptide-1 Analogue Versus Amylin as an Adjuvant Therapy in Type 1 Diabetes in a Closed Loop Setting With ePID Algorithm , 2014, Journal of diabetes science and technology.

[17]  Lauren M. Huyett,et al.  Closed-Loop Artificial Pancreas Systems: Engineering the Algorithms , 2014, Diabetes Care.

[18]  Roderike Pohl,et al.  Development of Stable Liquid Glucagon Formulations for Use in Artificial Pancreas , 2014, Journal of diabetes science and technology.

[19]  C. Cobelli,et al.  Artificial Pancreas: Past, Present, Future , 2011, Diabetes.

[20]  Benyamin Grosman,et al.  Automated hybrid closed‐loop control with a proportional‐integral‐derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance , 2017, Pediatric diabetes.

[21]  Ahmad Haidar,et al.  Outpatient 60‐hour day‐and‐night glucose control with dual‐hormone artificial pancreas, single‐hormone artificial pancreas, or sensor‐augmented pump therapy in adults with type 1 diabetes: An open‐label, randomised, crossover, controlled trial , 2017, Diabetes, obesity & metabolism.

[22]  D. BretonMarc,et al.  Adding heart rate signal to a control-to-range artificial pancreas system improves the protection against hypoglycemia during exercise in type 1 diabetes. , 2014 .

[23]  Link,et al.  UvA-DARE ( Digital Academic Repository ) Closing the loop , squaring the circle : Studies on insulin delivery , glucose monitoring and the artificial , 2013 .

[24]  Ole K. Hejlesen,et al.  The effect of alcohol on blood glucose in Type 1 diabetes - metabolic modelling and integration in a decision support system , 2003, Int. J. Medical Informatics.

[25]  Patrick Keith-Hynes,et al.  A Review of Safety and Design Requirements of the Artificial Pancreas , 2016, Annals of Biomedical Engineering.

[26]  Dale E. Seborg,et al.  Randomized Crossover Comparison of Personalized MPC and PID Control Algorithms for the Artificial Pancreas , 2016, Diabetes Care.

[27]  Linda D. Voss,et al.  Age Before Stage: Insulin Resistance Rises Before the Onset of Puberty , 2012, Diabetes Care.

[28]  R. Hovorka,et al.  Psychosocial aspects of closed‐ and open‐loop insulin delivery: closing the loop in adults with Type 1 diabetes in the home setting , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[29]  A. Brazeau,et al.  Carbohydrate counting accuracy and blood glucose variability in adults with type 1 diabetes. , 2013, Diabetes research and clinical practice.

[30]  Anirban Roy,et al.  Effect of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults With Type 1 Diabetes , 2012, Diabetes Care.

[31]  Roman Hovorka,et al.  Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. , 2014, The lancet. Diabetes & endocrinology.

[32]  David M Nathan,et al.  Autonomous and continuous adaptation of a bihormonal bionic pancreas in adults and adolescents with type 1 diabetes. , 2014, The Journal of clinical endocrinology and metabolism.

[33]  Ahmad Haidar,et al.  A Simplified Semiquantitative Meal Bolus Strategy Combined with Single- and Dual-Hormone Closed-Loop Delivery in Patients with Type 1 Diabetes: A Pilot Study. , 2016, Diabetes technology & therapeutics.

[34]  Ahmad Haidar,et al.  Efficacy of single-hormone and dual-hormone artificial pancreas during continuous and interval exercise in adult patients with type 1 diabetes: randomised controlled crossover trial , 2016, Diabetologia.

[35]  Laura Sciacca,et al.  Integrated insulin pump therapy with continuous glucose monitoring for improved adherence: technology update , 2015, Patient preference and adherence.

[36]  Moshe Phillip,et al.  Factors associated with increased risk of insulin pump discontinuation in pediatric patients with type 1 diabetes , 2011, Pediatric diabetes.

[37]  Ahmad Haidar,et al.  Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. , 2015, The lancet. Diabetes & endocrinology.

[38]  Janet M. Allen,et al.  Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies , 2011, BMJ : British Medical Journal.

[39]  Roman Hovorka,et al.  Home Use of an Artificial Beta Cell in Type 1 Diabetes. , 2015, The New England journal of medicine.

[40]  R. Koops,et al.  Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home , 2016, Diabetes, obesity & metabolism.

[41]  M. Joubert,et al.  Personal continuous glucose monitoring (CGM) in diabetes management: review of the literature and implementation for practical use. , 2012, Diabetes research and clinical practice.

[42]  Tarunraj Singh,et al.  Blood glucose control algorithms for type 1 diabetic patients: A methodological review , 2013, Biomed. Signal Process. Control..

[43]  Ahmad Haidar,et al.  Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial , 2013, Canadian Medical Association Journal.

[44]  Malgorzata E. Wilinska,et al.  Safety and Efficacy of 24-h Closed-Loop Insulin Delivery in Well-Controlled Pregnant Women With Type 1 Diabetes , 2011, Diabetes Care.

[45]  K. Kuehl,et al.  Randomized trial of a dual‐hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor‐augmented pump therapy , 2016, Diabetes, obesity & metabolism.

[46]  Thomas Danne,et al.  New insulins and insulin therapy. , 2013, Diabetes technology & therapeutics.

[47]  Ahmad Haidar,et al.  Closed-Loop Insulin Delivery During Pregnancy Complicated by Type 1 Diabetes , 2011, Diabetes Care.

[48]  Aaron J. Kowalski,et al.  Juvenile Diabetes Research Foundation Artificial Pancreas Consortium Update , 2009, Journal of diabetes science and technology.

[49]  L. Heinemann,et al.  Insulin Infusion Set: The Achilles Heel of Continuous Subcutaneous Insulin Infusion , 2012, Journal of diabetes science and technology.

[50]  Stuart A. Weinzimer,et al.  Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide , 2016, Diabetes Care.

[51]  Kellee M Miller,et al.  The T1D Exchange clinic registry. , 2012, The Journal of clinical endocrinology and metabolism.

[52]  F. Doyle,et al.  Design of the Glucose Rate Increase Detector , 2014, Journal of diabetes science and technology.

[53]  Kimberly N. Walter,et al.  The need for research addressing alcohol use disorder and diabetes. , 2016, Addiction.

[54]  B Wayne Bequette,et al.  Fault Detection and Safety in Closed-Loop Artificial Pancreas Systems , 2014, Journal of diabetes science and technology.

[55]  D. BretonMarc,et al.  Multinight "bedside" closed-loop control for patients with type 1 diabetes. , 2015 .

[56]  BolinderJan,et al.  New Insulins and Insulin Therapy , 2014 .

[57]  Benyamin Grosman,et al.  Day and Night Closed-Loop Control Using the Integrated Medtronic Hybrid Closed-Loop System in Type 1 Diabetes at Diabetes Camp , 2015, Diabetes Care.

[58]  David Kerr,et al.  Day after the night before: influence of evening alcohol on risk of hypoglycemia in patients with type 1 diabetes. , 2005, Diabetes care.

[59]  E. Atlas,et al.  Nocturnal glucose control with an artificial pancreas at a diabetes camp. , 2013, The New England journal of medicine.

[60]  W. Kenneth Ward,et al.  A Controlled Study of the Effectiveness of an Adaptive Closed-Loop Algorithm to Minimize Corticosteroid-Induced Stress Hyperglycemia in Type 1 Diabetes , 2011, Journal of diabetes science and technology.

[61]  G. Steil,et al.  Feasibility of Automating Insulin Delivery for the Treatment of Type 1 Diabetes , 2006, Diabetes.

[62]  Niels Kjølstad Poulsen,et al.  Model-Based Closed-Loop Glucose Control in Type 1 Diabetes: The DiaCon Experience , 2013, Journal of diabetes science and technology.

[63]  Ali Cinar,et al.  Classification of Physical Activity , 2015, Journal of diabetes science and technology.

[64]  Roman Hovorka,et al.  Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. , 2016, The New England journal of medicine.

[65]  Claudio Cobelli,et al.  2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. , 2015, The lancet. Diabetes & endocrinology.

[66]  J Hans DeVries,et al.  Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours. , 2014, Diabetes technology & therapeutics.

[67]  Ahmad Haidar,et al.  Single- and Dual-Hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes. , 2016, The Journal of clinical endocrinology and metabolism.

[68]  Howard C. Zisser,et al.  Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report , 2016, Diabetes Care.

[69]  Tadej Battelino,et al.  MD-Logic Overnight Control for 6 Weeks of Home Use in Patients With Type 1 Diabetes: Randomized Crossover Trial , 2014, Diabetes Care.

[70]  Marc D. Breton,et al.  Safety of Outpatient Closed-Loop Control: First Randomized Crossover Trials of a Wearable Artificial Pancreas , 2014, Diabetes Care.